Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Prostate cancer risk assessment tools in an unscreened population.

Lundon DJ, Kelly BD, Foley R, Loeb S, Fitzpatrick JM, Watson RW, Rogers E, Durkan GC, Walsh K.

World J Urol. 2015 Jun;33(6):827-32. doi: 10.1007/s00345-014-1365-7. Epub 2014 Aug 5.

PMID:
25091862
2.

Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T.

BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5.

3.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

4.

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.

BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.

5.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
6.

Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE.

BJU Int. 2011 Oct;108(8 Pt 2):E237-44. doi: 10.1111/j.1464-410X.2011.10207.x. Epub 2011 Apr 20.

7.

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.

Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.

8.

Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.

Foley RW, Lundon DJ, Murphy K, Murphy TB, Galvin DJ, Watson RW.

Ir J Med Sci. 2015 Sep;184(3):701-6. doi: 10.1007/s11845-015-1291-8. Epub 2015 Apr 7.

PMID:
25843017
9.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ.

World J Urol. 2012 Apr;30(2):181-7. doi: 10.1007/s00345-011-0818-5. Epub 2011 Dec 31.

10.

Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.

Park JY, Yoon S, Park MS, Choi H, Bae JH, Moon DG, Hong SK, Lee SE, Park C, Byun SS.

PLoS One. 2017 Jan 3;12(1):e0168917. doi: 10.1371/journal.pone.0168917. eCollection 2017. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175606.

11.

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Louie KS, Seigneurin A, Cathcart P, Sasieni P.

Ann Oncol. 2015 May;26(5):848-64. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17. Review.

PMID:
25403590
12.

Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, Chung BH.

Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665.

13.

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.

BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.

PMID:
27743489
14.

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW.

World J Urol. 2012 Apr;30(2):149-55. doi: 10.1007/s00345-011-0804-y. Epub 2011 Dec 28.

15.

Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.

Jeong CW, Lee S, Jung JW, Lee BK, Jeong SJ, Hong SK, Byun SS, Lee SE.

PLoS One. 2014 Apr 7;9(4):e94441. doi: 10.1371/journal.pone.0094441. eCollection 2014.

16.

A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM.

Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27.

PMID:
25454615
17.

The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.

Wu YS, Zhang N, Liu SH, Xu JF, Tong SJ, Cai YH, Zhang LM, Bai PD, Hu MB, Jiang HW, Na R, Ding Q, Sun YH.

Asian J Androl. 2016 Nov-Dec;18(6):925-929. doi: 10.4103/1008-682X.181192.

18.

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK.

Eur Urol. 2013 Feb;63(2):201-9. doi: 10.1016/j.eururo.2012.07.030. Epub 2012 Jul 20.

PMID:
22854248
19.

Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction.

Oliveira M, Marques V, Carvalho AP, Santos A.

BJU Int. 2011 Jun;107(11):1780-3. doi: 10.1111/j.1464-410X.2010.09727.x. Epub 2010 Sep 30.

20.

A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.

Lee A, Lim J, Gao X, Liu L, Chia SJ.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e348-e355. doi: 10.1111/ajco.12596. Epub 2016 Sep 19.

PMID:
27641069

Supplemental Content

Support Center